Insight

Jul 12, 2024, 11:24

What comes after sotorasib and adagrasib?

Aakash Desai, Thoracic/Phase 1 Oncologist at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent paper titled “The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?” published in Lung Cancer Journal.

Authors: Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi. .

“KRAS, once ‘undruggable,’ now sotorasib and adagrasib, but efficacy is limited.

Next-gen KRAS G12C/non-G12Ci and innovative approaches like molecular shielding and protein degradation are on the horizon!

Combos with SHP2/SOS1 inhibitors, chemo, or immune checkpoint inhibitors are being explored to tackle resistance.
Great review in Lung Cancer Journal.”

Source: Aakash Desai/X

Aakash Desai Adagrasib cancer G12C/non-G12Ci Kazuyoshi Imaizumi KRAS Lung Cancer Journal molecular shielding OncoDaily Oncology Research Sotorasib Tetsuya Mitsudomi UAB O'Neal Comprehensive Cancer Center Yuko Oya

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage